External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><ul><li>PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference<br>in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US<br>$1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).</li><li>Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.</li><li><div><div><div><div><p>VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.</p></div></div></div></div></li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

PYC Therapeutics recently presented at the Canaccord Genuity Growth Conference in Boston, MA, as well as direct peers Regulus Therapeutics (RGLS-NASDAQ: US $1.59 | BUY, TP US$28.00 | Whitney Ijem, Canaccord Genuity LLC), which also has an ADPKD asset, and broader industry feedback within the ophthalmology segment (Kiora Pharmaceuticals - KPRX-NASDAQ).Retinitis Pigmentosa 11 (RP11) updates provide early proof of concept, with more potential catalysts to come.VP-001 received the most attention in the presentation and discussions, given recent positive updates showing improved visual function in the treated eyes of two patients.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics

PYC Therapeutics Limited - Flash Update